Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone

Abstract Background Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (ABI) have a higher cardiovascular (CV) event-related hospitalization risk than those treated with enzalutamide (ENZA). This study aimed to assess CV event risk in ch...

全面介紹

書目詳細資料

Principais autores:	Alan H. Bryce, David Nimke, Christopher Young, Qiujun Shao, Nigel Rozario, Pinal Kamdar, Jasmina Ivanova, Irene Varghese, Maelys Touya
格式:	Artigo
語言:	Inglês
出版:	BMC 2026-03-01
叢編:	Cardio-Oncology
主題:	Androgen-receptor pathway inhibitor CV disease CV events Major adverse cardiac events mCRPC
在線閱讀:	https://doi.org/10.1186/s40959-026-00465-3
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!